Special Issue

Exploring Biomarkers and Pharmacotherapies for Substance Use Disorders

Message from the Guest Editors

This is a Special Issue with a focused objective of identifying behavioral, genetic, and epigenetic mechanisms involved in drug addiction, as well as potential new pharmacological agents for treating these disorders in both human and animal models.

Substance Use Disorders (SUD), encompassing alcohol, cannabis, stimulants, and other substances, pose a significant global health burden, impacting millions of people worldwide. Despite the profound consequences of these disorders on individuals, families, and societies, effective and precise diagnostic and therapeutic approaches remain limited. Therefore, it is imperative to identify the specific biomarkers associated with different stages of the disease, aiming to deepen our understanding of the underlying alterations and explore effective pharmacological interventions.

To summarize, we aim to cover all the essential aspects that can contribute to our enhanced comprehension of the biological basis of addiction and the identification of pharmacological interventions for treating SUD.

Guest Editors

Dr. Ani Gasparyan

Dr. Daniela Navarro

Prof. Dr. Jorge Manzanares

Deadline for manuscript submissions

closed (27 June 2025)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/181254

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

